Virtus Investment Partners (VRTS) Stock Price, Quote & News

Company Profile

Virtus Investment Partners, Inc. is a publicly owned investment manager. The firm primarily provides its services to individual and institutional clients. It launches separate client focused equity and fixed income portfolios. The firm launches equity, fixed income, and balanced mutual funds for its clients. It invests in the public equity, fixed income, and real estate markets. The firm also invests in exchange traded funds. It employs a multi manager approach for its products. The firm employs...

Industry: Asset Management

Sector: Financial Services

Phone: 800-248-7971

Website: corporate.virtus.com

Address:

One Financial Plaza, Hartford, United States

macrossluvsrobotech Sep. 1 at 3:47 PM

$LXRX $NVO $VRTS $BIB $SPY

0 · Reply

macrossluvsrobotech Sep. 1 at 3:45 PM

$LXRX dip is the seller’s loss. First principles: Value ≈ P(approval) × payoff, and P just rose. STENO1 hit the FDA exposure bar in late August, showing DKA rates matching standard of care and well below inTandem—clearing the historical ~3.5 DKA/100 patient-years gating variable. Q4 NDA resubmission brings the first oral insulin adjunct for T1D glycemic control to ~1M US adults. Bayes prior: Administrations deliver high-salience, kitchen-table health wins into midterms (like the IRA $35 insulin cap in Aug '22). Amid soft jobs and sticky inflation, a non-injectable T1D option is prime political currency. Sellers just handed shares over while the clock runs toward filing. N/FA. Zynquista refiling overview This short video provides a quick overview of Lexicon's regulatory timeline and plans for refiling Zynquista in type 1 diabetes. $NVO $BIB $VRTS https://youtu.be/NPGAZFACUoc?si=N7pwImDrGAxveMWM

0 · Reply

macrossluvsrobotech Aug. 31 at 4:56 PM

$LXRX $NVO $VRTS $BIB $LLY $LXRX Viral "China cured diabetes" posts mash TWO separate, early-stage trials into a fake national rollout 'news'. 1️⃣ 2024 Cell Study: Only 1 patient, who was already on heavy anti-rejection drugs from a prior liver transplant. 2️⃣ 2026 Lancet Study (E-islet01): Just 3 patients. Mixed results, requires lifelong immunosuppression, and costs $150K+ per custom surgery with no retail price or approval. REALITY: Boutique experimental surgeries are years away from mass scale. They are NOT products you can buy today. WHY IT MATTERS FOR $LXRX: Complex cell procedures with lifelong drug risks can’t help millions right now. That's why accessible, daily oral treatments like Zynquista remain the urgent, scalable winner for Type 1 Diabetes! 📈 NFA Youtube video From Chinese News Service: CNS : https://youtu.be/FdGvAK9qSf0?si=19AM01nKREMtalp5

0 · Reply

macrossluvsrobotech Aug. 31 at 4:42 PM

$LXRX viral “China cured diabetes” posts mash TWO studies. Not a product. 2024 Cell (Deng/Tianjin): ONE published T1D woman. Off insulin day 75. Already on liver-transplant immuno. 1-year paper. Not this weekend. https://www.cell.com/cell/fulltext/S0092-8674(24)01022-5 2026 Lancet (E-islet01, Shanghai): THREE T1D cases. Pt1 first graft FAILED. Redo + heavy immuno: 54→8 units, not off. Pt2 off insulin >26 mo. Pt3 56→16 units, not off. Needs immuno. No list price. China/US IND only. Not approved. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00423-1/fulltext Boutique transplant ≠ 2026 pill. Does not move Zynquista Q4 2026 file. $NVO $VRTS $BIB $LLY

0 · Reply

macrossluvsrobotech Aug. 31 at 3:49 PM

$LXRX :Why Low-BP Matters 🫀 BP (Blood Pressure) is the force of blood against artery walls (Systolic top number over Diastolic bottom). SBP is Systolic Blood Pressure (the top number when the heart beats). Normally, doctors fear treating fragile heart failure patients with SBP < 110 ( lower than 110) (top number under 110 mmHg) because meds can crash BP ( Blood Pressure ) or cause kidney stress. Lexicon's new trial data solves this. Sotagliflozin achieved an HR 0.56 (Hazard Ratio), meaning patients on the drug had 56% of the adverse events of placebo ( ALMOST HALF!!), vs 100% , 100 minus 56 = a 44% reduction in CV (Cardiovascular)-death/HF ( Heart Failure) events. Physically, it unloads heart fluid via dual SGLT1/2 inhibition without crashing BP or causing kidney injury (zero difference vs placebo). The point: INPEFA is safe and effective when BP ( Blood Pressure) is low! $NVO $VRTS $BIB $LLY

0 · Reply

macrossluvsrobotech Aug. 31 at 3:29 PM

$LXRX Cardio Landscape NEWS TODAY in Plain English! 🫀📊 $LLY latest Cardio News Today , how it affects $LXRX Cardio treatment: 1. LLY MOUNJARO: FDA approved to cut MACE (heart attacks/strokes). Trial was vs Trulicity ($LLY's older GLP-1) showing HR 0.92 (8% risk cut). Mounjaro targets plaque; INPEFA clears fluid in heart failure. They don't compete—doctors use both! $CYTK recent news, how it affects $LXRX 2. CYTK SAFETY FLAW: Aficamten (myosin inhibitor) turns down heart squeeze. Symptom gains were tiny (KCCQ +3.0), but 10.5% suffered a dangerous heart pump drop (LVEF <50% vs 0.8% placebo). Pump tax! $LXRX’s SONATA-HCM treats stiff hearts WITHOUT weakening the pump. 3. LXRX NEW DATA TODAY: Analyzed low blood pressure patients (top number SBP <110). Sotagliflozin delivered HR 0.56 = 44% reduction in CV death & HF events (p=0.03) with ZERO excess kidney damage or fainting vs placebo. Proves safety in fragile patients! $NVO $VRTS PR: https://lexiconpharma.gcs-web.com/news-releases/news-release-details/lexicon-announces-new-post-hoc-soloist-whf-analysis

0 · Reply

macrossluvsrobotech Aug. 28 at 2:21 PM

$LXRX LXRX THEY ARE SELLING YOU BOTH ALPHA AND AN INFLATION HEDGE, WAR HEDGE, OIL HEDGE AT A FIRESALE PRICE, BECAUSE THEY CAN'T TAKE THE TIME TO READ THE HCM RESULTS, FROM $CYTK . $CYTK = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN SOTAGLIFLOZIN) PHASE 3 RESULTS ( TELLS THE HEART TO SLOW DOWN, DUE TO INFLEXIBLE HEART MUSCLE WALL, BRINGING HEART DANGEROUSLY CLOSE TO STOPPING ALL TOGETHER) = BAD VS $LXRX = HCM ( A COMPLETELY DIFFERENT CHEMICAL PATHWAY THAN $CYTK, ) SOTAGLIFLOZIN FROM $LXRX HELPS THE MUSCLE WALL ITSELF BECOME MORE FLEXIBLE AND DOES NOT SLOW DOWN THE HEART ITSELF = GOOD ) PHASE 3 RESULTS = GOOD. $NVO $VRTS $BIB

1 · Reply

macrossluvsrobotech Aug. 28 at 2:03 PM

$LXRX :What the Big Heart Trial News ACTUALLY Means (Plain English) Competitor Cytokinetics dropped Phase 3 data for stiff-heart disease (nHCM). Here is the layman breakdown: 1. KCCQ (+3.0 pts): A 0-100 symptom questionnaire. A 3-pt gain is barely noticeable to patients. 2. Peak VO2 (+0.67): Oxygen used during max exercise. +0.67 is just a few extra seconds on a treadmill. 3. LVEF <50% (10.5% vs 0.8%): Ejection Fraction is heart pump strength (normal = 50-70%). 10.5% of patients had their heart pump dangerously weakened into heart failure territory! The Takeaway for Lexicon ($LXRX): The competing class works by putting a "speed limiter" on the heart motor, but it risks stalling the pump. Lexicon’s drug (sotagliflozin in Phase 3 SONATA-HCM) works differently: it improves cellular energy and reduces stiffening WITHOUT weakening the heart pump. This safety scare blows the door wide open for $LXRX. Full SEC & Trial Data: https://investors.lexpharma.com $CYTK $NVO $BIB $VRTS

0 · Reply

Synaptric Aug. 5 at 8:11 PM

A complete mixed bag of sentiments ahead of Thursday morning earning reports. Software name $DDOG was extremely bearish early in this period and is now showing as extremely bullish. It is joined there by $CELH which ranked extremely bullish several times. $VRTS took a circuitous path to the lowest in sentiment rank. Interesting to see three Industrials (UUU, DNOW, and HWM) clustered at neutral. The two energy names ($COP and LNG) have faded considerably the past few days as have many in that group.

0 · Reply

StocktwitsEarnings Jul. 30 at 11:10 AM

$VRTS Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $6.79 up 9.87% YoY • Reported revenue of $201.36M down -4.35% YoY

0 · Reply

Virtus Investment reports preliminary AUM of $147.5B as of August 31

Sep 11, 2026, 8:00 AM EDT - 2 days ago

Virtus Investment Partners Reports Preliminary August 31, 2026 Assets Under Management

Aug 20, 2026, 4:30 PM EDT - 24 days ago

Virtus Investment Partners Announces Appointment of Board Member

2026-08-20T11:10:31.000Z - 24 days ago

Virtus Investment board increases quarterly dividend to $2.45 per share

Aug 20, 2026, 7:00 AM EDT - 24 days ago

Virtus Investment Partners Increases Quarterly Common Stock Dividend to $2.45 Per Share

Aug 17, 2026, 4:15 PM EDT - 27 days ago

Virtus Introduces Two Actively Managed ETFs from Zevenbergen

2026-08-17T09:42:17.000Z - 27 days ago

Virtus Investment reports preliminary AUM of $148.9B as of July 31

Aug 12, 2026, 8:00 AM EDT - 4 weeks ago

Virtus Investment Partners Reports Preliminary July 31, 2026 Assets Under Management

2026-07-31T09:20:27.000Z - 6 weeks ago

Virtus Investment price target lowered to $135 from $141 at Barclays

Jul 30, 2026, 10:00 AM EDT - 6 weeks ago

Virtus Investment Partners Earnings Call Transcript: Q2 2026

Jul 30, 2026, 10:00 AM EDT - 6 weeks ago

Virtus Investment Partners Earnings release: Q2 2026

Jul 30, 2026, 10:00 AM EDT - 6 weeks ago

Virtus Investment Partners Slides: Q2 2026

Jul 30, 2026, 10:00 AM EDT - 6 weeks ago

Virtus Investment Partners Quarterly report: Q2 2026

Jul 30, 2026, 7:00 AM EDT - 6 weeks ago

Virtus Investment Partners Announces Financial Results for Second Quarter 2026

2026-07-29T16:30:37.000Z - 6 weeks ago

Virtus Investment price target raised to $130 from $119 at Morgan Stanley

Jul 20, 2026, 4:15 PM EDT - 7 weeks ago

Virtus Introduces Virtus InfraCap Preferred and Income Securities ETF

2026-07-20T12:45:49.000Z - 7 weeks ago

Virtus Investment price target raised to $147 from $136 at TD Cowen

2026-07-14T09:45:14.000Z - 2 months ago

Virtus Investment price target raised to $141 from $125 at Barclays

Jul 13, 2026, 4:15 PM EDT - 2 months ago

Virtus Investment Partners to Announce Second Quarter 2026 Financial Results on Thursday, July 30

2026-07-13T12:15:17.000Z - 2 months ago

Virtus Investment reports preliminary AUM of $152.2B as of June 30

Jul 13, 2026, 8:00 AM EDT - 2 months ago

Virtus Investment Partners Reports Preliminary June 30, 2026 Assets Under Management

Jul 5, 2026, 9:36 AM EDT - 2 months ago

Dividend Growth Stock List: 8 Names Yielding Up To 8.3%

AGX CHE FIX HESM HWM MO TMUS

2026-06-26T12:50:13.000Z - 2 months ago

Virtus Investment price target raised to $119 from $112 at Morgan Stanley

Jun 15, 2026, 7:00 AM EDT - 3 months ago

Virtus Investment Partners Slides: Investor presentation

2026-06-10T12:22:19.000Z - 3 months ago

Virtus Investment reports preliminary AUM of $153.1B as of May 31

Jun 10, 2026, 8:00 AM EDT - 3 months ago

Virtus Investment Partners Reports Preliminary May 31, 2026 Assets Under Management

2026-05-22T20:20:09.000Z - 3 months ago

Virtus Investment files automatic mixed securities shelf

May 21, 2026, 7:00 AM EDT - 3 months ago

Virtus Investment Partners Declares Quarterly Cash Dividend on Common Stock

2026-05-19T12:05:40.000Z - 3 months ago

Virtus Investment price target lowered to $112 from $128 at Morgan Stanley

May 17, 2026, 11:00 AM EDT - 3 months ago

The Most Hated High Yields On Wall Street

ALX CAG CPB GIS IMXI KHC PSEC

2026-05-12T16:01:03.000Z - 4 months ago

Virtus Investment reports preliminary AUM of $154.8B as of April 30

May 12, 2026, 8:00 AM EDT - 4 months ago

Virtus Investment Partners Reports Preliminary April 30, 2026 Assets Under Management

2026-05-04T12:50:14.000Z - 4 months ago

Virtus Investment price target lowered to $131 from $132 at TD Cowen

2026-05-04T11:57:49.000Z - 4 months ago

Virtus Investment price target lowered to $170 from $180 at Piper Sandler

2026-05-04T09:35:49.000Z - 4 months ago

Virtus Investment price target lowered to $125 from $128 at Barclays

May 1, 2026, 10:00 AM EDT - 4 months ago

Virtus Investment Partners Earnings Call Transcript: Q1 2026

May 1, 2026, 10:00 AM EDT - 4 months ago

Virtus Investment Partners Earnings release: Q1 2026

May 1, 2026, 10:00 AM EDT - 4 months ago

Virtus Investment Partners Slides: Q1 2026

May 1, 2026, 10:00 AM EDT - 4 months ago

Virtus Investment Partners Quarterly report: Q1 2026

May 1, 2026, 7:00 AM EDT - 4 months ago

Virtus Investment Partners Announces Financial Results for First Quarter 2026

Apr 22, 2026, 4:42 PM EDT - 4 months ago

Virtus Introduces Virtus Silvant Small/Mid Growth ETF

2026-04-20T14:23:13.000Z - 4 months ago

Virtus Investment price target lowered to $132 from $135 at TD Cowen

2026-04-17T09:25:13.000Z - 4 months ago

Virtus Investment price target lowered to $128 from $142 at Barclays

Apr 15, 2026, 4:47 PM EDT - 5 months ago

Virtus Introduces Virtus Duff & Phelps Real Estate Income ETF

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Virtus Investment Partners Reports Preliminary March 31, 2026 Assets Under Management

Apr 13, 2026, 8:00 AM EDT - 5 months ago

Virtus Investment Partners Proxy statement: Proxy filing

Apr 10, 2026, 4:15 PM EDT - 5 months ago

Virtus Investment Partners to Announce First Quarter 2026 Financial Results on Friday, May 1

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Virtus Investment Partners Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Virtus Investment Partners Proxy statement: Proxy filing

Mar 11, 2026, 7:00 AM EDT - 6 months ago

Virtus Investment Partners Reports Preliminary February 28, 2026 Assets Under Management

Mar 2, 2026, 8:58 AM EST - 6 months ago

Virtus Investment Partners Closes on Investment in Keystone National Group

Mar 2, 2026, 6:00 AM EST - 6 months ago